Aurinia Pharmaceuticals (TSE:AUP) Reaches New 1-Year High at $11.30

Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$11.30 and last traded at C$11.13, with a volume of 360073 shares changing hands. The stock had previously closed at C$10.61.

Several brokerages recently issued reports on AUP. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, October 17th. Bloom Burton reissued a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 2nd.

The company has a debt-to-equity ratio of 0.31, a quick ratio of 9.99 and a current ratio of 10.26. The stock has a market capitalization of $906.47 million and a P/E ratio of -16.15. The stock’s fifty day simple moving average is C$7.48 and its two-hundred day simple moving average is C$7.88.

In other Aurinia Pharmaceuticals news, Senior Officer Bradley Dickerson bought 5,000 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, October 14th. The shares were purchased at an average cost of C$5.11 per share, with a total value of C$25,542.00. Following the acquisition, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately C$76,626. Insiders have acquired a total of 9,550 shares of company stock worth $53,567 over the last three months.

Aurinia Pharmaceuticals Company Profile (TSE:AUP)

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: What are different types of coverage ratios?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with's FREE daily email newsletter.